Pluri Inc. (PluriStem Therapeutics Inc.) 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on June 23, 2017, by PluriStem Therapeutics Inc., a Nevada corporation headquartered in Haifa, Israel. The report discloses executive compensation adjustments and equity grants effective July 1, 2017, following the appointment of Mr. Yaky Yanay as Co-Chief Executive Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Mr. Yaky Yanay (Co-CEO & President): Annual base salary increased from NIS 637,500 (~$177,000) to NIS 960,000 (~$267,000). Additionally, he receives a $20,000 annual director fee.
- Mr. Zami Aberman (Co-CEO & Chairman): No salary change disclosed; received equity grant.
Material Changes
The primary material change is the increase in executive compensation and the issuance of restricted stock to retain leadership:
- Salary Increase: Mr. Yanay's salary increased by approximately $90,000 annually.
- Equity Grants: Both Mr. Yanay and Mr. Aberman received 2,000,000 restricted shares each (4,000,000 total). Grants were split between the 2016 Equity Compensation Plan and the Amended and Restated 2005 Stock Option Plan.
- Vesting Schedule: 12.5% vests at the 6-month anniversary; the remainder vests in 14 equal quarterly installments over the subsequent 3.5 years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of risks and contingencies. The context implies a strategic focus on executive retention during a leadership transition.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2016 and 2005 Equity Plans to assess dilution impact.
- Confirm the exact exchange rate used for the NIS to USD conversion in the salary increase.
- Review the full vesting conditions and potential acceleration clauses in the executive employment agreements.
- Check subsequent filings for any further changes to the executive team or compensation structure.